Anzeige
Mehr »
Sonntag, 19.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856877 | ISIN: JP3197800000 | Ticker-Symbol: OMR1
Tradegate
17.10.25 | 07:35
23,800 Euro
-2,46 % -0,600
1-Jahres-Chart
OMRON CORPORATION Chart 1 Jahr
5-Tage-Chart
OMRON CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
23,80024,60017:41
24,20024,40017.10.
PR Newswire
356 Leser
Artikel bewerten:
(2)

OMRON HEALTHCARE Co., Ltd.: OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold

- Reinforcing Commitment to Preventive Cardiovascular and Home Blood Pressure Monitoring -

KYOTO, Japan, Sept. 29, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in innovative medical equipment for preventive healthcare, announced that cumulative worldwide sales of OMRON blood pressure monitors (BPMs) have exceeded 400 million units. This landmark achievement underscores the company's longstanding commitment to extending healthy life expectancy by advancing home blood pressure monitoring and preventive cardiovascular care.

Logo:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI1fl_k2sj30Cw.png

Image:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI2fl_68Qw97R2.png

The journey began over half a century ago, with the launch of the first OMRON-branded BPM in 1973, when all blood pressure measurement was conducted at medical facilities. Nowadays, thanks to advances in technology, anyone can easily and accurately measure their own blood pressure at home, and OMRON Healthcare has continued to drive the evolution of blood pressure management to support preventive healthcare, including efforts to detect potentially life-threatening conditions such as atrial fibrillation (AFib) at an early stage.

As a new chapter begins, OMRON Healthcare's industry-leading devices and digital health platforms continue to transform daily monitoring into a powerful tool for the protection of global health. With distribution in over 130 countries and regions worldwide, OMRON Healthcare is committed to ensuring access to accurate, cost-effective home blood pressure monitors in emerging markets where preventive healthcare resources remain limited, working to reduce health disparities by enabling early detection and intervention in communities most at risk.

"Reaching 400 million units sold is more than a number -- it represents the trust that millions of people place in OMRON Healthcare to support their journey toward longer, healthier lives," said Ayumu Okada, President and CEO, OMRON HEALTHCARE Co., Ltd. "The quality and accuracy of OMRON blood pressure monitors are well recognized by healthcare professionals around the world. We remain dedicated to 'Going for ZERO' vision, aiming to eradicate cerebro-cardiovascular events globally by developing technologies that connect daily life and healthcare, empowering people everywhere to take preventive action. We will continue to promote innovative products, services, and educational efforts to raise awareness of hypertension risks -- not only for those already diagnosed, but also for those who may not yet realize they are at risk."

https://healthcare.omron.com/going-for-zero/400-million

Innovation for Preventive Care
Building on over 50 years of expertise, OMRON Healthcare continues to advance technology that transforms blood pressure monitors into essential preventive care devices, through innovations including:

- Connected digital health monitoring: Bluetooth-enabled devices integrate with the OMRON connect app, supporting trend visualization, family sharing, and physician oversight.

- AI-powered detection: Unique, FDA-cleared Intellisense AFib technology enables early recognition of atrial fibrillation during routine monitoring.

- Integrated measurement: Complete monitor combines blood pressure and ECG readings, seamlessly shareable with physicians via the OMRON connect app.

- Remote monitoring partnerships: OMRON's Digital Health Business continues to expand with the acquisition of new subsidiary Luscii, and strategic partnerships with international companies.

About OMRON Healthcare: https://kyodonewsprwire.jp/attach/202509195504-O1-1133eHlN.pdf

For more information, please visit:
Website: https://healthcare.omron.com/
LinkedIn: https://www.linkedin.com/company/omron-healthcare-co-ltd-/

Cision View original content:https://www.prnewswire.co.uk/news-releases/omron-healthcare-exceeds-400m-blood-pressure-monitors-sold-302569172.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.